Clinical effect of Yunnan Hongyao capsules combined with atorvastatin on elderly patients with residual hematoma after chronic subdural hematoma surgery
Zhu Feng
Chen Xuefei
Zhang Chunliang
Liu Qiang
Li Fang
Abstract：Objective To explore the clinical effect of Yunnan Hongyao capsules combined with atorvastatin on elderly patients with residual hematoma after chronic subdural hematoma (CSDH) surgery.Methods Seventy-six elderly patients with residual CSDH after surgery were enrolled from October 2013 to October 2015 in the Second Central Hospital of Baoding,Hebei Province;they were randomly divided into control group and observation group,with 38 cases in each group.The control group took atorvastatin after surgery and the observation group took atorvastatin and Yunnan Hongyao capsules for 1 month.Hematoma volume 1,3 months after treatment,the 1-month clinical effective rate,scores of the Activity of Daily Living Scale (ADL) and the Chinese stroke scale (CSS) before and 1 month after treatment,adverse reactions during treatment and the 6-,12-,18-month recurrence rates were analyzed.Results There was no significant difference of hematoma volume between groups before treatment(P ＞0.05);1,3 months after treatment,hematoma volume significantly decreased compared to that before treatment,and it was significantly less in observation group than that in control group(P ＜ 0.05).One month after treatment,the clinical effective rate in observation group was significantly higher than that in control group[89.5％ (34/38) vs 68.4％ (26/38)] (x2 =5.067,P =0.024).There were no significant differences of ADL and CSS scores between groups before treatment (P ＞ 0.05);1 month after treatment,the ADL score was significantly higher and the CSS score was significantly lower than those before treatment;the ADL score after treatment in observation group were significantly higher and the CSS score was significantly lower than those in control group(P ＜ 0.05).The adverse reaction rate had no significant difference between groups(P ＞ 0.05).The 12-and 18-month recurrence rates in observation group were significantly lower than those in control group [7.9％ (3/38) vs 28.9％ (11/38),7.9％ (3/38) vs 34.2％ (13/38)] (P ＜ 0.05).Conclusion Combined use of atorvastatin and Yunnan Hongyao capsules treating elderly patients with residual CSDH can effectively reduce hematoma volume,improve neurological function and activity of daily living,reduce recurrence risk and improve the prognosis.
Keywords：Chronic subdural hematomaYunnan Hongyao capsulesAtorvastatin
Publication Date：2018-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 392-396 )